Medtronic and Abbott both offer long dividend records, but they solve different portfolio problems. Medtronic provides more current income and trades at a lower valuation. Abbott offers a faster recent dividend increase, stronger long-run share performance and a broader mix of medical devices, diagnostics, nutrition and established pharmaceuticals. For a retiree, the correct comparison is not simply which yield is higher; it is which company can fund its dividend through the next operating setback without sacrificing growth.
Medtronic’s income advantage is real
Medtronic’s quarterly dividend is $0.72, or $2.88 annualized. Using the roughly $88 share price reported by 24/7 Wall St., the forward yield is about 3.3%. Abbott’s $0.63 quarterly dividend equals $2.52 annually and about a 2.5% yield near the reported $100.57 price.
That 0.8-percentage-point gap is meaningful. On a $100,000 investment at those prices, the initial annual income is roughly $3,273 from Medtronic versus $2,506 from Abbott before taxes and reinvestment—a difference of about $767. The calculation assumes the dividends remain unchanged and ignores trading costs, price movements and fractional-share constraints.
Medtronic also has a 49-year record of annual increases. Its latest increase from $0.71 to $0.72 per quarter was only about 1.4%, so the high starting yield comes with slow recent growth. Abbott’s increase from $0.59 to $0.63 was about 6.8%, and the company says it has paid a dividend for 410 consecutive quarters. Investors who need income now may prefer Medtronic; investors with a long reinvestment horizon may place more weight on Abbott’s faster growth.
Coverage looks similar, but the cash context differs
Medtronic’s $2.88 annual dividend equals 48.4% of the midpoint of its official fiscal 2027 non-GAAP EPS guidance of $5.90 to $6.00. Abbott’s $2.52 dividend equals 45.6% of the midpoint of its 2026 adjusted EPS guidance of $5.45 to $5.60. These adjusted payout ratios are close, and both leave an accounting cushion.
Adjusted earnings are not cash. Medtronic generated $7.33 billion of operating cash flow and $5.43 billion of free cash flow in fiscal 2026. The gap of about $1.90 billion reflects capital expenditures in the company’s free-cash-flow definition. That cash supports dividends, debt service, share repurchases and product investment.
For dividend durability, the useful coverage test is free cash flow after the ordinary investment required to keep the product portfolio competitive. Medical-device companies must fund clinical programs, regulatory work and manufacturing capacity before distributing residual cash. A payout ratio based only on adjusted EPS can look comfortable while cash is being absorbed by inventory, receivables or restructuring. Medtronic’s disclosed free cash flow gives investors a direct anchor; Abbott’s acquisition period makes comparable cash disclosure especially important.
Abbott’s current cash picture includes the financing and integration of Exact Sciences, whose acquisition closed on March 23. Second-quarter interest expense rose materially in the figures reported by 24/7 Wall St. The deal expands Abbott’s cancer-diagnostics exposure, including Cologuard, but also raises the importance of integration, debt and cash conversion. A faster dividend increase is encouraging; it does not eliminate acquisition risk.
Operating growth favors different narratives
Medtronic reported fiscal 2026 revenue growth that management described as its strongest annual performance in a decade, and guided to 6.75% to 7.25% organic growth for fiscal 2027. The company’s official release also showed fiscal 2026 GAAP EPS of $3.73 and non-GAAP EPS of $5.53. Constant-currency non-GAAP EPS declined 2%, demonstrating that revenue acceleration had not yet produced equally strong per-share earnings growth.
That tension is central to the Medtronic case. Product momentum in areas such as cardiac ablation can lift organic sales, but mix, investment, foreign exchange and planned portfolio changes still determine the earnings conversion. The proposed diabetes separation adds another variable: it may sharpen the remaining company’s focus, yet execution and capital-allocation effects are not fully known.
Abbott’s second-quarter 2026 sales rose 13% on a reported basis and 4.8% on an organic basis, with adjusted EPS of $1.31. Medical Devices sales reached $5.85 billion and grew 8.4% organically, while Nutrition sales fell 3.1%. Management raised full-year adjusted EPS guidance to $5.45 to $5.60 and maintained an organic sales growth outlook of 6.5% to 7.5%.
The portfolio reduces reliance on any single device category, but diversification can hide crosscurrents. Device growth must offset weaker nutrition, and Exact Sciences must add enough strategic and financial value to justify its purchase price and financing burden. Abbott’s long record supports confidence; current execution still matters.
Valuation changes the required outcome
The October 6 comparison from 24/7 Wall St. estimated forward P/E ratios near 15 times for Medtronic and 17 times for Abbott, with trailing ratios around 22 and 32. Those market estimates are dated and use different earnings bases, so they should be treated as directional rather than precise. They indicate that investors are paying more for Abbott’s growth and consistency.
A premium is defensible when organic growth, dividend growth and cash conversion remain superior. It becomes vulnerable if integration costs rise, device growth slows or interest expense absorbs more earnings. Medtronic’s lower multiple provides more room for imperfect execution, but a cheap stock can stay cheap if EPS growth continues to lag sales and the portfolio transition creates uncertainty.
How long until Abbott’s dividend catches up?
A simple illustration clarifies the trade-off. If Medtronic’s dividend grows 1.4% annually and Abbott’s grows 6.8%, Abbott’s annual dividend would approach Medtronic’s after roughly three years: $2.52 compounded at 6.8% for three years is about $3.07, while $2.88 compounded at 1.4% is about $3.00. This is a scenario, not a forecast; boards approve dividends quarter by quarter, and growth rates can change.
The illustration shows why time horizon matters. A retiree spending the distributions today receives more cash from Medtronic immediately. An investor reinvesting for a decade may benefit more from Abbott if its faster growth persists. Share-price changes and taxes can easily outweigh the dividend difference, so the comparison should sit inside a diversified income plan rather than determine it.
Inflation changes the comparison further. A slowly growing dividend can lose purchasing power even when the nominal payment never falls. Abbott’s faster recent increase offers a better inflation offset if it persists, whereas Medtronic’s higher initial yield provides more current cash that can be spent or reinvested. Neither advantage is permanent: growth depends on earnings, and yield changes whenever the share price or board-approved dividend changes.
The evidence that would change the choice
Medtronic strengthens its case by converting guided organic growth into EPS and free-cash-flow growth, clarifying the diabetes separation and accelerating dividend growth without raising the payout burden. Abbott strengthens its case by maintaining high-single-digit device growth, stabilizing Nutrition, integrating Exact Sciences and keeping cash generation ahead of rising interest and dividend commitments.
For current income, Medtronic is the more compelling starting point: the yield advantage is substantial, adjusted payout coverage is comparable and the valuation is lower. For investors prioritizing long-duration dividend growth, Abbott can justify its lower yield if operating growth and integration execution remain strong. The decisive difference is not the length of either dividend streak. It is whether future cash flow supports the kind of income each investor actually needs.